Portfolio company
Focalis
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Focalis Bio develops gene therapies delivering engineered potassium channels to treat patients suffering from focal refractory epilepsy.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
EpilepsyGTx
This company develops precision gene therapies for patients with focal refractory epilepsy to provide seizure freedom.
Corlieve Therapeutics
The company develops gene therapies for patients with refractory temporal lobe epilepsy and other severe neurological disorders.
Neurosciences
This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.
GenEp
The company develops therapies targeting ion channel mutations to treat rare genetic and treatment-resistant epilepsies for patients with unmet medical needs.
Axonis
This biotechnology company develops oral small molecule therapies targeting the KCC2 protein to treat patients with epilepsy, chronic pain and spinal cord injuries.
ViaNautis
ViaNautis develops polymer-based nanovesicles to deliver genetic medicines across biological barriers for patients with central nervous system and respiratory diseases.
Lario Therapeutics
This company develops precision medicines for patients with severe neurological disorders, including epilepsy and Parkinson’s disease.
Coave Therapeutics
The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.